Dual mTOR Inhibitor MLN0128 in Advanced Castration-Resistant Prostate Cancer (CRPC) Patients

This study has been terminated.
(Slow accrual)
Sponsor:
Collaborator:
Millennium Pharmaceuticals, Inc.
Information provided by (Responsible Party):
Memorial Sloan Kettering Cancer Center
ClinicalTrials.gov Identifier:
NCT02091531
First received: March 14, 2014
Last updated: November 18, 2015
Last verified: November 2015
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been terminated.
  Estimated Study Completion Date: No date given
  Primary Completion Date: November 2015 (Final data collection date for primary outcome measure)